key: cord-0979320-80ml4oy0 authors: Li, J.; Xia, W.; Zhan, C.; Liu, S.; Yin, Z.; Wang, J.; Chong, Y.; Zheng, C.; Fang, X.; Cheng, W.; Reinhardt, J. D. title: Effectiveness of a telerehabilitation program for COVID-19 survivors (TERECO) on exercise capacity, pulmonary function, lower limb muscle strength, and quality of life: a randomised controlled trial date: 2021-03-09 journal: nan DOI: 10.1101/2021.03.08.21253007 sha: 7613dfd24dc4b56a19b9d0c59a4c1c612f037ce8 doc_id: 979320 cord_uid: 80ml4oy0 Objectives To investigate superiority of a telerehabilitation program for Covid-19 (TERECO) over no rehabilitation with regard to functional exercise capacity, lower-limb muscle strength (LMS), pulmonary function, health-related quality of life (HRQOL), and perceived dyspnoea. Design Parallel-group randomised controlled-trial with 1:1 block-randomisation. Setting Three major hospitals from Jiangsu and Hubei provinces, China. Participants 120 Covid-19 survivors with modified Medical Research Council (mMRC) dyspnoea score of 2-3 who had been discharged from hospital were randomised. 61 were allocated to the control group and 59 to the TERECO group. Intervention The control group received educational instructions. The TERECO group participated in a 6-week home-based, pulmonary rehabilitation program delivered via smartphone and monitored with chest-worn heart rate telemetry. Exercise types comprised breathing control and thoracic expansion, aerobic exercise, and LMS exercise. Outcomes Primary outcome was 6-minute walking distance (6MWD) in metres. Secondary outcomes were LMS measured as squat time in seconds; pulmonary function assessed by spirometry with parameters being forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, maximum voluntary ventilation (MVV), and peak expiratory flow; HRQOL measured with SF-12 physical component score (PCS) and mental component score (MCS); and mMRC dyspnoea, favourable outcome (no dyspnoea). Outcomes were assessed at 6 weeks (post-treatment) and 28 weeks (follow-up). Results 120 patients were randomised, 15 (12.5%) were lost to follow-up at study endpoint. No serious adverse events occurred. 38 participants in the TERECO group complied with the exercise protocol (64.41% of randomized). The adjusted between-group difference in change in 6MWD from baseline was 65.45 metres (95% CI 43.8-87.1, p<0.001) at post-treatment and 68.62 metres (95% CI 46.39-90.85, p<0.001) at follow-up. Treatment effects for LMS were 20.12 seconds (95% CI 12.34-27.9, p<0.001) post-treatment and 22.23 seconds (95% CI 14.24-30.21, p<0.001) at follow-up. No group differences were found for lung function apart from post-treatment MVV (10.57 litres/minute, 95% CI 0.26-17.88, p=0.005). Increase in SF-12 PCS was greater in the TERECO group with treatment effects estimated as 3.79 (95% CI 1.24-6.35, p=0.004) at post-treatment and 2.69 (95% CI 0.06-5.32, p=0.045) at follow-up. No significant between-group differences were found for improvements in SF-12 MCS. At post-treatment 90.4% endorsed a favourable outcome for mMRC dyspnoea in the TERECO group vs. 61.7% in control (adjusted RR 1.46, 1.17-1.82, p=0.001). Conclusions This trial demonstrated superiority of TERECO over no rehabilitation for 6MWD, LMS, and SF-12 PCS. We found no persistent effects on pulmonary function, SF-12 MCS, and perceived dyspnoea. Trial registration: Chinese Clinical Trial Registry: ChiCTR2000031834, 11 Apr 2020, URL: http://www.chictr.org.cn/showproj.aspx?proj=52216 After discharge from acute care, many survivors of coronavirus disease-2019 (Covid-19) 95 experience ongoing symptoms 1 2 , impairment of pulmonary function 2-4 , decreased exercise 96 capacity 2 4 , reduced muscle strength 5 , activity limitations 6 7 , anxiety 7 , depression and 97 neurocognitive dysfunction 8 , and reduced quality of life 2 . Problems may persist for at least six 98 months 2 . This indicates the need for the provision of rehabilitation services that can decrease the 99 Aerobic exercise was performed by brisk walking or running outside near the home or on a 194 treadmill at home (if available to the participant) with a 3-minute warm-up and 3-minute 195 stretching cool-down. The target heart rate (THR) for aerobic exercise was calculated with the 196 Karvonen formula 18 , with exercise intensity scheduled to increase from 30-40% of heart rate 197 reserve (HRR) at the beginning of the exercise program to 40-60% of HRR in the final two weeks 198 of the program. Apart from monitoring the actual heart rate, patients were asked to report their 199 rate of perceived exertion (RPE) after the aerobic exercises according to Borg's scale 19 20 . When 200 this RPE was greater than 14, the current intensity was considered unsuitable and the THR for a 201 participant was lowered. When the reported RPE was below 11, participants were requested to 202 increase their aerobic exercise intensity. When the reported RPE ranged between 11 and 14, 203 participants repeated the exercise at the same intensity and moved to the next tier after 2 weeks. 204 (iii) LMS exercise comprised weight-bearing and resistance exercises 21 and gradually moved 205 from exercises performed in a sitting position such as seated leg lifting to exercises executed in 206 standing position such as squats and side lunges. 207 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint On each day with scheduled exercises, RehabApp reminded the patients to start the exercise 210 and guided them through the process. In the case of BCTE and LMS exercise this was done by 211 displaying videos demonstrating the relevant exercises. During aerobic exercise, information on 212 the patients' HR in relation to the THR was displayed on the smartphone screen. When the 213 monitored HR was within the THR range, RehabApp recorded the duration as effective exercise 214 and illuminated a green light at the bottom of the screen. When the monitored HR was below or 215 over the THR, a yellow or red light appeared, respectively. If the HR exceeded 110% of the 216 target heart rate, the patient received a message to slow down the exercise until the HR returned 217 to resting rate. RehabApp recorded the HR, the total duration of the exercise, the duration of the 218 effective exercise, self-reported RPE and any interruptions if they occurred. 219 Compliance with exercise protocol 220 Total exercise time for a given day was determined as the time from opening to closing 221 RehabApp. The time during aerobic exercise within which the monitored HR reached the THR or 222 above was counted as effective exercise time. Having reached at least two thirds (66.7%) of the 223 scheduled total and effective target time as given in Table 1 or modified by the therapist in any 224 given week for at least five of the six weeks according to RehabApp records was considered 225 compliant with the exercise protocol. 226 Assessments were conducted between 26 April and 9 December 2020. For each patient home 228 visits were scheduled at baseline, at six weeks (post-treatment), and at 24 weeks (follow-up). 229 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. If a patient could not complete the 6MWT, the distance walked until interruption was recorded. 248 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Participants were asked to perform a squat with their back against the wall starting from a 252 standing position, feet flat on the ground, and approximating a 90° angle at the hip and knees. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 20 Given limited knowledge about the longer-term course of the disease including spontaneous 290 recovery as well as learning effects that may occur, a more conservative MID of 50 metres was 291 assumed here. To achieve 80% power with an alpha error of 5%, a minimal sample size of 96 292 participants (48 per group) was needed to detect a statistically significant signal for a 293 between-group difference in change in 6MWD (with SD 99 in control and SD 71 in the 294 intervention group as reported by Lau for a trial in a SARS population 11 ). Assuming 20% attrition 295 our recruitment target was 120 participants (60 per group). 296 All analyses were performed with STATA 14.0. All main analyses were conducted on 298 intention-to-treat (ITT) basis and without imputations. Statistical significance was set at alpha = 5% 299 with two-sided tests. No corrections for multiplicity were applied. The predefined statistical 300 analysis plan (SAP) is available in Appendix 1. 301 Data were assumed to be missing at random (MAR) with missing values depending on observed 303 model parameters 31 . This assumption was tested with sensitivity analysis as described below. 304 The primary outcome, change in 6MWD post-treatment, was evaluated with constrained 305 longitudinal data analysis (cLDA), that is a linear mixed effects model that imposed an equality 306 constraint on baseline means 32 33 . Dependence of longitudinal observations within study 307 participants was modelled with a random intercept. The fixed part of the model included time 308 points and interactions between time points and treatment group (but no term for treatment group 309 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 21 at baseline), and a term for study centre. This model is equivalent to longitudinal analysis of 310 covariance (ANCOVA) if there are no missing data. However, in the presence of missing data, 311 cLDA also considers data from participants who only participated in the baseline assessment. 312 The parameters for the interaction terms between time and treatment represent the estimated 313 treatment effects at the two follow-up points and are reported with 95% confidence intervals (CIs). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 22 logistic model originally specified in the SAP due to ease of interpretation of rate ratios and 330 derivation of population-averaged probabilities. A graphical illustration of trajectories presents 331 marginal means and probabilities (mMRC dyspnoea) for the intervention group and time point as 332 estimated with the above models with 84% CIs serving as comparisons bars. 84% CIs allow for 333 visual inspection for approximate statistical significance of mean differences at alpha = 5% by 334 looking at the overlap of CIs. 35 335 Pre-specified sensitivity analysis included estimation of the above models on the per protocol 337 sample, as well as on two types of multiply imputed datasets. Firstly, multiple imputation with 338 chained equations 36 was performed under an extended MAR assumption, i.e. that missing 339 values were also dependent on observed values of (auxiliary) variables not included in the 340 models used for primary analysis. These were gender, age, disease severity, time from first 341 hospital admission for Covid-19 to baseline assessment, presence of comorbidities, smoking 342 history, and body mass index. Models were estimated on 70 imputed data sets as the 343 originally-specified 50 data sets (see SAP) did not yield a satisfactory upper limit for the fraction 344 of missing information 37 . Secondly, controlled multiple imputation (50 sets) was used for 345 simulating a non-MAR scenario where patients with missing assessments in the TERECO group 346 followed the pattern of change in controls (copy increments in reference -CIR). 38 347 As the follow-up assessment could not take place at home as planned due to change in 348 administrative regulations pertaining to Covid-19 as previously noted, a delay in the planned 349 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Deviations from the SAP (ii-iv) had no effect on the statistical significance of estimates when 368 compared with analyses as originally planned. 369 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Of those 20 were ineligible or refused consent. 120 patients were randomised with one person in 381 the TERECO group and one in the control group not receiving the allocated intervention. One 382 patient was withdrawn from the TERECO group before the start of the exercise program as a 383 premature beat was discovered. One patient in the control group had been randomised 384 mistakenly because the assessor forgot to inform the allocator about the patient's ineligibility due 385 to refusal to collaborate in the baseline 6MWT and pulmonary function assessment (see 386 exclusion criterion vi). Other data from this patient were not included in the analysis. Six patients 387 of the TERECO group did not complete the post-treatment assessment. We lost contact with four 388 patients of which one had previously announced to discontinue the intervention for unspecified 389 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 25 reasons. Two patients who discontinued the intervention, one because of chest pain and one for 390 unspecified reasons, missed the post-treatment assessment but returned for the follow-up 391 assessment. We had lost contact with four additional patients in the TERECO group and five 392 patients from the control group at the final follow-up point. 393 Baseline characteristics of the study participants by intervention group are provided in Table 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 28 § Unless otherwise stated. ǂ Cases were defined as severe when patients met one of the following criteria at any time during 404 hospitalization: acute respiratory distress, respiratory rate ≥30 breath/min; pulse oxygen saturation (SpO2) ≤93% at rest; arterial blood 405 partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤300 mmHg (1 mmHg = 0.133 kPa ); respiratory failure requiring 406 mechanical ventilation; septic shock; failure of other organs requiring ICU treatment. 39 407 * n=112 (control=60, intervention=52). ** n=105 (control=55, intervention=50). *** For spirometry n=115 (control=57, Table 3 gives an overview of crude change and adjusted treatment effects for all outcomes. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. at follow-up. Lung function parameters improved in both group over time (Figure 2) . No group 447 differences were found apart from an adjusted between-group difference in change from 448 baseline of 10.57 litres per minute (95% CI 3.26-17.88, p=0.005) in post-treatment MVV in favour 449 of the TERECO group. This between-group difference was reduced to 5.2 litres per minute (95% 450 CI -2.33-12.73) at follow-up and was no longer statistically significant (p=0.176). SF-12 PCS 451 increased to a larger degree in the TERECO group as compared to the control group with 452 treatment effects estimated as 3.79 points (95% CI 1.24-6.35, p=0.004) at the post-treatment 453 assessment and 2.69 (95% CI 0.06-5.32, p=0.045) at follow-up. The lower limit of the 95% CI of 454 the between-group difference was however close to zero at follow-up. Improvement in SF-12 455 MCS was somewhat greater in the TERECO group but 95% CIs were also compatible with 456 greater improvement in the control group at both assessment points. With 90.4% endorsing a 457 favourable outcome for dyspnoea in the TERECO group as opposed to 61.7 percent in the 458 control group (adjusted RR 1.46, 1.17-1.82, p=0.001), a treatment effect for perceived dyspnoea 459 was found immediately after the intervention period but not at the other time points. 460 Estimates from sensitivity analysis are provided in Table 4 . Per protocol analysis showed larger 462 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. was unstable in all pre-planned sensitivity analyses. Estimates from post hoc sensitivity analysis 470 that added parameters for TOS to the models were almost identical with those from main 471 analysis. 472 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Primary outcome: 6MWD in meters -post-treatment (6 weeks) More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis 658 medRxiv (preprint) 2021 6-month consequences of COVID-19 in 660 patients discharged from hospital: a cohort study Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Impact of coronavirus disease 2019 on 666 pulmonary function in early convalescence phase Muscle 668 Strength and Physical Performance in Patients Without Previous Disabilities Recovering 669 From COVID-19 Pneumonia. American journal of physical medicine & rehabilitation No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9 Low physical functioning 672 and impaired performance of activities of daily life in COVID-19 patients who survived 673 hospitalisation Prevalence and risk factors of disability 675 and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease Covid-19) from China Persistent 678 psychopathology and neurocognitive impairment in COVID-19 survivors: effect of 679 inflammatory biomarkers at three-month follow-up Rehabilitation needs of the first cohort of 681 post-acute COVID-19 patients in Hubei, China. European journal of physical and 682 rehabilitation medicine 2020 Pulmonary rehabilitation 684 for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 685 A randomised controlled trial of the 687 effectiveness of an exercise training program in patients recovering from severe acute 688 respiratory syndrome Rehabilitation and 690 COVID-19: a rapid living systematic review 2020 by Cochrane Rehabilitation Field European journal of physical and rehabilitation 692 medicine 2021 Postacute Care Preparedness for COVID-19: Thinking 694 Effectiveness of Telerehabilitation in Physical Therapist Practice: An 697 Umbrella and Mapping Review with Meta-Meta-Analysis Telerehabilitation 699 for chronic respiratory disease. The Cochrane database of systematic reviews The significance of respiratory symptoms 702 and the diagnosis of chronic bronchitis in a working population ACSM's Guidelines for Exercise Testing and 705 Prescription 9th ed. Philadelphia The effects of training on heart rate Perceived exertion as an indicator of somatic stress. Scandinavian journal of 709 rehabilitation medicine No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9 Psychophysical bases of perceived exertion. Medicine and science in sports and 711 exercise Lower-extremity resistance training on unstable surfaces improves proxies of 713 muscle strength, power and balance in healthy older adults: a randomised control trial Respiratory Society/American Thoracic Society technical standard: field walking tests in 717 chronic respiratory disease The effects of modified wall squat exercises on average adults' deep abdominal 719 muscle thickness and lumbar stability Recommendations 722 for a Standardized Pulmonary Function Report. An Official Multi-ethnic reference 725 values for spirometry for the 3-95-yr age range: the global lung function National compilation of reference values of pulmonary function SF-36 total score as a single measure of health-related quality of life: 731 Scoping review A 12-Item Short-Form Health Survey: construction of 733 scales and preliminary tests of reliability and validity Medical Research Council dyspnea scale in the estimation of disease severity in 736 idiopathic pulmonary fibrosis 739 measurement properties of field walking tests in chronic respiratory disease. The 740 Statistical Analysis with Missing Data To condition or not condition? Analysing 'change' in 743 longitudinal randomised controlled trials Different ways to 745 estimate treatment effects in randomised controlled trials Extension of the modified Poisson regression model to prospective 748 studies with correlated binary data The graphical presentation of a collection of means Multiple imputation using chained equations: Issues and 753 guidance for practice How Many Imputations Do You Need? A Two-stage Calculation Using a 755 Sensitivity analysis for clinical trials with 757 missing continuous outcome data using controlled multiple imputation: A practical guide National Health Commission of the PR China Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) Home-based or 763 remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic 764 and beyond: A rapid review Respiratory function in patients post-infection by COVID-19: a systematic review 767 and meta-analysis Effects of Home-Based Breathing Exercises Apart from estimates for mMRC perceived dyspnoea (favourable outcome), estimates are between-group differences in mean change from baseline derived from linear mixed effects 474 models adjusted for study centre (fixed effect) and with baseline means constrained to be equal across comparison groups. Estimates for mMRC perceived dyspnoea are rate ratios In this trial, the TERECO program was superior to the control group regarding improvement of 504 functional exercise capacity (6MWD), LMS (squat time), and the physical component of HRQOL 505 (SF-12 PCS). All these effects could be sustained over a 7-months period. Pronounced 506 differences in exercise capacity and lower-limb muscle strength remained between intervention 507 and control group. For physical HRQOL, the difference between TERECO and the control group 508 decreased at the final follow-up due to improvements in the control group. We also found a 509 short-term effect of TERECO on MVV and mMRC perceived dyspnoea. Both effects, however, 510 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. included. The results are thus not generalizable to persons with no, mild or severe dyspnoea, nor 526 to people who contracted SARS CoV-2 but were not hospitalised for it. Another important 527 weakness is the unexpected change of the location and resulting delay of the final follow-up 528 assessment because regulations pertinent to the protection of health professionals from infection 529 no longer permitted assessment visits. While conditions remained the same between 530 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 38 intervention and control group, it is unclear how this may have affected patient-reported 531 assessments and pulmonary function testing. Low-certainty evidence (one randomised 532 crossover trial) suggests that 6MWT performed outdoors yields comparable results to 533 centre-based testing. 40 Emerging evidence suggest that most profound impairment of lung 534 function in Covid-19 occurs in diffusion capacity 2 41 usually measured as the diffusion capacity of 535 the lung for carbon monoxide (CO) or the transfer capacity for CO. This was unclear at the time 536 of study design and the required measurement procedures are difficult to perform in the home 537 setting. Comparability of the occurrence of adverse events across groups during the intervention 538 period was also limited by additional prompts in the intervention group issued in weekly 539 consultations with therapists and through RehabApp. Recollection bias in the control group is 540 possible, for instance, rather mild events that happened several days ago might not have been 541 remembered during two-weekly phone interviews. Finally, this trial was not powered for 542 subgroup analysis and effect sizes in specific subpopulations hence remain unclear. 543At the time of writing, there are no other randomised-controlled studies on rehabilitation 544 effectiveness for Covid-19. Demonstrating clinically meaningful and sustainable effects of the 545 TERECO program on 6MWD and LMS, this study also adds to previous low-certainty evidence 546 on the effectiveness of telerehabilitation in respiratory disease. 15 The effect size for 6MWD in the 547 present study at six weeks is comparable to results from a randomized-controlled trial from Hong 548 Kong by Lau and associates 11 who evaluated a 6-week outpatient exercise program for SARS 549 survivors with baseline and post-treatment assessment. In contrast to our findings, the latter 550 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 39 study did not detect any effects of the program on quality of life (SF-36) or lower-limb strength 551 (measured as gluteus maximum and anterior deltoid strength with dynamometer). While a recent 552 systematic review and meta-analysis reported superior effects of breathing exercise on lung 553 function parameters (FEV1 and FEV1/FVC) as compared to control for COPD 42 , no such effects 554 were found in the present study. In contrast to COPD, Covid-19 does not necessarily involve 555 permanent impairment of structures of the lung and patients in our study from both groups seem 556 to have naturally improved regarding lung function parameters. Another possible explanation is 557 that the BCTE exercises included in the TERECO program were not sufficiently targeted. 558 Moreover, compliance with this exercise type is difficult to measure remotely. Similar to the 559 HRQOL physical component, mental aspects of quality of life also improved in both groups but 560 no statistically significant between-group differences in increments were detected at any point, 561 although the SF-12 MCS score of the TERECO group remained at about 2 points above control 562 at follow-up. This result is difficult to interpret due to the unavailability of an MID for SF-12 in the 563 target population. It is possible that our study was simply underpowered to detect a clinically 564 relevant difference. In contrast to HRQOL, the proportion of patients free of subjective dyspnoea 565 clearly decreased in the TERECO group between a peak at post-treatment and follow-up, 566 returning to about the value at four weeks and suggesting that effects on perceived dyspnoea 567 could not be sustained. 568The TERECO program is targeted at improving physical fitness including physical aspects of 569 subjective HRQOL and should be applied in populations with respective deficits. Effects of the 570 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 40 program on pulmonary function are unlikely while those on mental well-being remain unclear. 571Components better targeting these outcomes could be added in future evaluations of similar 572 programs. For example, low-to moderate-quality evidence for the effectiveness of Tai-Chi in 573 improving lung function in persons with COPD exists. 43 The TERECO program appears to be 574 safe but more mild adverse events occurred in the TERECO group in the first 6 weeks. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Special thanks go to Dr. Yongqiang Li, Puyang Zhang, Wei Zhang, and Wenzhong Zou. We cordially 607 thank all study participants and our other patients with Covid-19 for their feedback and ideas on how 608 to design and improve the TERECO program. We thank Jiayi Zhang for cross-checking the English 609 translation of the Chinese protocol. We like to thank our friend and linguistics expert Dr. Michael 610 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. China during the conduct of the study. No other relationships or activities exist that could appear 630 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Anonymised patient-level data on which the analysis, results, and conclusions reported in this 646 paper are based will be shared on a public digital repository upon publication of the paper. 647 Transparency declaration 648 JL and JDR affirm that the manuscript is an honest, accurate, and transparent account of the 649 study being reported; that no important aspects of the study have been omitted; and that any 650 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We have reported whether we plan to disseminate the results to study participants and or patient 653 organisations or stated that dissemination to these groups is not possible/applicable. 654 655 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 48 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21253007 doi: medRxiv preprint 500 520 540 560 580